Exelixis Inc (NASD: EXEL):
30 January 2018, Tuesday, 3.28pm Singapore Time
(Click on Technical Chart above to Expand)
Attached above is the technicals for Exelixis, a company that is listed in the NASDAQ. Exelixis is a genomics-based drug discovery company, and the producer of Cometriq, a treatment approved by the FDA for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. It holds a number of high value biomedical patents. The orange region shows the first high volume absorption of Exelixis at $24 region. Blue circled regions are the deliberate volume absorptions at $23-$28 region. Green circled regions are impulsive buys at $25-$28 region. Fellow smart monies in Wall Street have a lot of deliberate buys on Exelixis at $23-$28 region in conclusion. We are currently not far from their buys. Expect +100% upside from this stock. This stock is supported with moving average rising uptrends.
The Donovan Norfolk Technical Rating:
Very Bullish
(Strong Buy)
No comments:
Post a Comment